Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed August 2026
Key Takeaways
- ATTR-CM epidemiology should be interpreted cautiously because underrecognition distorts it.
- Published burden reflects both disease biology and case detection and diagnostic evaluation.
- Age, referral enrichment, and phenotype selection all shape apparent prevalence.
Why ATTR-CM Epidemiology Has to Be Read Through Ascertainment
ATTR-CM epidemiology should be interpreted in the context of case ascertainment and diagnostic practices. Reported prevalence depends not only on disease occurrence but also on recognition, referral patterns, diagnostic evaluation, and confirmation of ATTR-CM. Reported prevalence is therefore influenced by case detection and diagnostic evaluation, highlighting the importance of clinical awareness and recognition of risk factors that prompt investigation for ATTR-CM.
Where Apparent Prevalence Rises
Reported prevalence is generally higher in populations with an increased likelihood of ATTR-CM detection, including older adults, selected heart failure cohorts, patients with aortic stenosis, and those evaluated in specialized referral centers. These differences largely reflect variations in case ascertainment, referral patterns, and diagnostic evaluation rather than true differences in disease occurrence.
Why the Safest Conclusion Is Directional
Current evidence suggests that ATTR-CM remains underdiagnosed and that reported prevalence estimates should be interpreted cautiously. ATTR-CM is likely underrecognized, especially where phenotype recognition is weak or confirmatory pathways are incomplete, and the reported disease burden is expected to change as diagnostic evaluation improves. Improved screening strategies, greater clinical awareness, and systematic diagnostic evaluation are likely to improve case detection and provide more accurate estimates of disease burden.
Frequently Asked Questions
Is ATTR-CM underdiagnosed?
Current evidence suggests that ATTR-CM remains underdiagnosed. Published prevalence is shaped by recognition, referral, and completion of the diagnostic pathway, so true burden is likely higher than counted, particularly where phenotype recognition is weak.
Why does ATTR-CM look more common in some settings than others?
ATTR-CM looks more common in some settings than others because suspicion is unevenly distributed. Older populations, selected heart failure cohorts, aortic stenosis pathways, and specialty referral streams concentrate cases, raising apparent prevalence relative to routine practice.
Should published prevalence figures be taken at face value?
They should be interpreted cautiously. Published prevalence estimates are influenced by case ascertainment and diagnostic evaluation and are likely to underestimate the true disease burden.
Related Reading
Part of the Spotlight On ATTR-CM resource center.
Understand the Disease
Confirm the Diagnosis
See the Evidence
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart
- Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. Journal of the American College of Cardiology
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.